Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa + apatinib + platinum chemotherapy in first-line advanced NSCLC
ChiCTR2600121692Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600121692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121692.